13F Holdings
中文EN

INBP INTEGRATED BIOPHARMA INC

Pharmaceutical Preparations · OTC · SEC CIK 1016504 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-23.1%
TTM net income YoY-644.0%
TTM EPS YoY-650.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin-0.8%
Operating margin-9.3%
Net margin-8.9%
FCF margin-3.8%
EBITDA margin-8.6%

Returns

ROE-19.5%
ROA-14.8%
ROIC (approx.)-20.4%
Asset turnover1.66x

Leverage & solvency

Liabilities / assets29.2%
Debt / equity0.00x
Current ratio2.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$43.87M$54.35M$50.32M$50.67M$56.25M
Cost of revenue$43.07M$48.79M$46.43M$46.61M$49.69M
Gross profit$800,000$5.56M$3.88M$4.06M$6.55M
SG&A expense$3.50M$3.54M$3.63M$3.94M$3.81M
Operating income-$2.71M$2.02M$251,000$120,000$2.75M
Interest expense$12,000$46,000$52,000$52,000$128,000
Pretax income-$2.56M$2.06M$268,000$100,000$2.60M
Income tax$279,000$1.25M$156,000$134,000-$1.24M
Net income-$2.84M$808,000$112,000-$34,000$3.84M
EBITDA-$2.41M$2.34M$558,000$471,000$3.08M
EPS (basic)-0.090.030.000.000.13
EPS (diluted)-0.090.030.000.000.12
Weighted avg. shares (diluted)31.06M31.17M30.87M29.95M32.32M
Balance sheet
Cash & equivalents$4.47M$3.62M$1.68M$1.32M$331,000
Receivables$3.33M$5.43M$4.67M$4.51M$4.89M
Inventory$9.14M$9.36M$11.24M$10.26M$11.05M
Current assets$17.38M$18.76M$17.88M$16.37M$16.63M
PP&E, net$1.75M$1.72M$1.80M$1.65M$1.91M
Total assets$25.34M$24.90M$26.21M$26.21M$25.25M
Current liabilities$5.80M$4.25M$6.12M$4.83M$5.26M
Short-term debt———$42,000$32,000
Long-term debt———$7,000$53,000
Total debt———$49,000$85,000
Total liabilities$7.67M$4.58M$6.97M$6.57M$6.67M
Shareholders' equity$17.67M$20.32M$19.24M$18.86M$18.57M
Net debt———-$1.27M-$246,000
Shares outstanding31.06M31.06M30.10M29.95M29.95M
Cash flow statement
Operating cash flow$1.24M$2.06M$943,000$1.23M$4.09M
Capital expenditure$346,000$191,000$553,000$116,000$486,000
Free cash flow$895,000$1.87M$390,000$1.12M$3.60M
Investing cash flow-$340,000-$205,000-$553,000-$111,000-$465,000
Financing cash flow-$45,000$78,000-$29,000-$136,000-$3.50M
Depreciation & amortization$293,000$318,000$307,000$351,000$336,000
Stock-based compensation$192,000$185,000$252,000$320,000$369,000

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.